# Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

> **NCT01804101** · NA · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Liposomal Cytarabine-Daunorubicin CPX-351

## Key facts

- **NCT ID:** NCT01804101
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-07
- **Primary completion:** 2017-01-10
- **Final completion:** 2017-01-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804101, "Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01804101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*